Clinical Trial News Archive - March 2013
Get news by email or subscribe to our news feeds.
March 1, 2013
March 4, 2013
- Polyphor reports successful Phase I results for its Pseudomonas selective antibiotic POL7080
- Landmark Phase III Data Confirms Velcade Significantly Improves Long-Term Overall Survival in Patients With Previously Untreated Multiple Myeloma
- InnaVirVax announces publication of an article in JAIDS (Journal of Acquired Immune Deficiency Syndromes)
- Phase III Study of Teva's Milprosa (Progesterone) Vaginal Ring Published in Fertility and Sterility
- Ventrus Biosciences Announces Poster Presentation on the Quality of Compounded Topical Diltiazem Hydrochloride Formulations for Anal Fissure at the American Pharmacists Association Meeting
- Endocyte's Investigational Diagnostic Imaging Agent Etarfolatide Identifies Ovarian Cancer and Non-Small Cell Lung Cancer Patients Most Likely to Benefit From Folate Receptor-Targeted Treatment, New Analysis Shows
- Argos Therapeutics Validates Durability of AGS-003 Induced Immune Response in mRCC Patients
- Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
- Researchers Describe First 'Functional HIV Cure' in an Infant
- Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
- VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study
- Tokai Pharmaceuticals to Present Data on Galeterone in Advanced Prostate Cancer at 2013 International Congress on Targeted Anticancer Therapies (TAT)
March 5, 2013
- Daily-Use HIV Prevention Approaches Prove Ineffective Among Women in NIH Study
- Sarepta's Marburg Drug Shows High Survival Rates After Intramuscular Delivery in Non-Human Primates
- Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
- First interim results from a phase IIa study evaluating an all-oral regimen of Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients
- Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevnar 13 In Adults With HIV
- Tobira Therapeutics Presents Positive Phase 2b Clinical Results For Cenicriviroc in Treatment-Naïve HIV Infection in Late Breaker Session at CROI
- Gilead Announces Full 24-Week Phase 2 Results for Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF)
- VIMPAT (lacosamide) generates positive results in U.S. Phase 3 monotherapy study
March 6, 2013
- InnaVirVax announces presentation of the results of its Phase I/IIa clinical study at CROI 2013 in Atlanta
- Prana's PBT434 Inhibits PD Protein & Brain Cell Death
- Santarus and VeroScience Announce Publication of AACE Expert Panel Recommendations for CYCLOSET (bromocriptine mesylate) for the Management of Type 2 Diabetes
- Progenics Pharmaceuticals' Novel Small Molecule Drugs Targeting PSMA Successfully Visualize Prostate Cancer
- Medivir: Results From a Phase IIa Study Evaluating Simeprevir and Sofosbuvir in Prior Null Responder Hepatitis C Patients Have Been Presented at CROI
- AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
- Targeted Medical Pharma Reports New Data on Red Blood Cell Stimulating Formulation
- Tosedostat OPAL Study in Acute Myeloid Leukemia Published in Lancet Oncology
- NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinson's Disease
March 7, 2013
- New Superiority Trial Showed LIVALO (pitavastatin) 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults with Dyslipidemia versus Pravastatin 40 mg
- Data from First Clinical Trial of GGF2 in Heart Failure Presented at the American College of Cardiology 62nd Annual Scientific Session
March 8, 2013
- Announcement of Results from a Japanese Phase 3 Clinical Trial on the Additional Indication of Chronic Pain for Fentos Tape (Development Code: HFT-290), a Transdermal Long-Acting Cancer Pain Relief Patch
- Proteostasis Therapeutics Presents Data at 11th International Conference on Alzheimer's and Parkinson's Diseases
- Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
March 11, 2013
- Gilead's Ranexa Reduces Angina Frequency in Study of Chronic Angina Patients With Type 2 Diabetes
- New trial results support treatment with Inspra (eplerenone) within first 24 hours of symptoms, in addition to standard therapy, in patients with acute STEMI without heart failure.
- VGTI Florida Scientists Reveal a Mystery of Diminished Immune Function in HIV Infection
- Early Detection of MS Treatment Complication May Improve Survival
- Can Hormone Help Treat Multiple Sclerosis Long-Term?
- The Boston Scientific PROMUS Element Platinum Chromium Stent Demonstrates Continued Low Event Rates Through Three Years
- Results from HPS2-THRIVE Study of TREDAPTIVE (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions
- Precision Therapeutics Announces Topline Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian Cancer using Personalized Chemotherapy Diagnostic ChemoFx®
- Presentation of Preliminary Results From Boston Scientific PREVAIL Clinical Trial Now Available
- Study: Therapeutic combination for HER2-positive breast cancer does not increase cardiac problems, but cancer patients? heart health should be monitored
- Niacin Causes Serious Unexpected Side-effects, but no Worthwhile Benefits, for Patients who are at Increased Risk of Heart Attacks and Strokes
- The Medicines Company's Intravenous Cangrelor Demonstrates 22% Reduction in Ischemic Events Compared to Oral Clopidogrel
- Retrophin Announces Positive Results from Preclinical Studies of RE-024 for PKAN
- Emerging Data From Upsher-Smith's CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
- Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation
- New Data Reinforce Strong Long-Term Clinical Performance of Abbott's Absorb Bioresorbable Vascular Scaffold
March 12, 2013
- Clinical Utility of Platelet Reactivity Strongly Advocated at ACC.13
- Cardiac Biomarker ST2 Identifies Chronic Heart Failure Patients To Benefit from High-Dose Beta Blocker Therapy
- ANAVEX 2-73 restores mitochondrial functionality, blocks cell death and oxidative stress, preventing onset of Alzheimer's disease
March 13, 2013
- Genzyme's Multiple Sclerosis Franchise Featured at AAN
- the Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnology?s CYT003 for the Treatment of Allergic Asthma
- Acorda to Present New Research on Novel Multiple Sclerosis and Epilepsy Therapies at American Academy of Neurology 65th Annual Meeting
- Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx
- Genomic Health Announces Positive Results from Large Study of Oncotype DX to Quantify Risk of Loco-Regional Recurrence in Node-positive Breast Cancer Patients and Acceptance of Oncotype DX DCIS Validation Study for Publication
- Islet Sciences Announces Important Study Published in Diabetes Titled ?Immune Therapy Reducing β-Cell Death in Type 1 Diabetes?
March 14, 2013
- Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function in Patients with Cancer Published in The Lancet Oncology
- Foundation Fighting Blindness Clinical Research Institute to Launch ProgStar Natural History Study for Stargardt Disease to Help Prepare for Future Clinical Trials
- Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neurology Annual Meeting
- Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for EV71 Vaccine Candidate Against Hand, Foot and Mouth Disease
March 15, 2013
- Antiviral Nasal Spray - Data From Two Clinical Studies Prove Effectiveness of Marinomed´S Antiviral Drug
- AMAG Pharmaceuticals Announces Positive Preliminary Results from an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing with Ferumoxytol in Patients with Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause
- Daiichi Sankyo Announces Results of PRASFIT-Elective Study Regarding Use of Prasugrel in Elective Patients with Stable Angina and Chronic Myocardial Infarction Undergoing PCI
March 18, 2013
- New Tysabri Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status
- Santarus Announces Publication in Gut of Results from UCERIS (budesonide) European Pivotal Clinical Study
- People With Type 2 Diabetes Achieve 6% Weight Loss With Liraglutide 3 Mg in Phase 3a Obesity Trial
- New Study of Cialis (tadalafil) Tablets Co-administered with Finasteride Meets Primary Endpoint in Men with Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia
- TheraVida Presents Positive Phase 2 Data for Tolenix (THVD-201) in Patients with Overactive Bladder at the 28th Annual Congress of the European Urological Association
- InSite Vision Announces Positive Phase 3 Results for BromSite? (ISV-303) for the Reduction of Inflammation and Pain after Cataract Surgery
March 19, 2013
- FDA Perspective Published in the New England Journal of Medicine Reinforces Safety of Pradaxa (dabigatran etexilate mesylate)
- Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
- Acasti Pharma Presents Preliminary Data Moving Forward With Clinical Strategy
- TheraVida Presents Positive Phase 2 Data for Tolenix (THVD-201) in Patients with Overactive Bladder at the 28 th Annual Congress of the European Urological Association
- HIV Trial Validates Novel Drug Mechanism
- InSite Vision Announces Positive Phase 3 Results for BromSite (ISV-303) for the Reduction of Inflammation and Pain after Cataract Surgery
- New Data Released on Switching Parkinson's Disease Patients with Pre-Existing Gastrointestinal Symptoms from Oral PD Medications to Neupro (Rotigotine Transdermal System)
March 20, 2013
- Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
- BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Development
- Positive Year One Results from Biogen Idec Phase 3 ADVANCE Trial of PLEGRIDY? (Peginterferon Beta-1a) Presented at AAN Meeting
- New Data Show Azilect (rasagiline tablets) Provided Clinical Benefit in Patients with Early Parkinson's When Added to Sub-Optimally Controlled Patients on Dopamine Agonist Therapy
- Diazepam Nasal Spray Demonstrates Comparable Bioavailability to Diazepam Rectal Gel in Pharmacokinetic Study
- Drug Does Not Significantly Reduce Risk of Death Among Patients With Severe Sepsis
- PsiOxus Therapeutics Comments on Phase III Results from Amgen's Oncolytic Vaccine
- Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
- BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for Schizophrenia
March 21, 2013
- Affinium Pharmaceuticals Announces Positive Efficacy, Safety, and Tolerability Results from Phase 2a Clinical Trial of Oral AFN-1252 in Acute Bacterial Skin & Skin Structure Infections
- New analysis shows Novartis drug Gilenya significantly reduced rate of brain volume loss across three large Phase III studies
- Early versus Delayed Treatment with Laquinimod Demonstrated Significant Reduction in Risk of Disability Progression ? Results of Three-Year ALLEGRO Study in Relapsing-Remitting Multiple Sclerosis
- Data From ISIS-SMN Rx Phase 1 Study in Children With Spinal Muscular Atrophy Presented at the American Academy of Neurology Meeting
- ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson's Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
- Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents With Atopic Dermatitis
- Ohr Pharmaceutical Announces Results from OHR/AVR118 Phase II Trial in Cancer Cachexia
- Results of Lymphoseek Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology
March 22, 2013
- Effect of Genzyme's Lemtrada Maintained in Patients Beyond Two-Year Pivotal MS Studies
- Cerulean Announces Results from Phase 2b Lung Cancer Trial
- New Data Released on Switching Parkinson's Disease Patients with Pre-Existing Gastrointestinal Symptoms from Oral PD Medications to Neupro (Rotigotine Transdermal System)
- Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
